Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1

Trial Profile

Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Apr 2014

At a glance

  • Drugs Beclabuvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Apr 2014 Results published in the Antimicrobial Agents and Chemotherapy.
    • 30 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jul 2009 Planned end date changed from 1 Jun 2009 to 1 Aug 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top